Laguna Hills, CA-based Volcano Therapeutics has signed a letter of intent to acquire the global intravascular ultrasound and functional measurement businesses of Jomed, a high-tech medical research company headquartered in Helsingborg, Sweden. Bankruptcy
Laguna Hills, CA-based Volcano Therapeutics has signed a letter of intent to acquire the global intravascular ultrasound and functional measurement businesses of Jomed, a high-tech medical research company headquartered in Helsingborg, Sweden. Bankruptcy is forcing Jomed to divest its assets, some of which were sold to Abbott Laboratories in June. The company plans to sell the remainder in the coming months. Volcano Therapeutics has tagged several as complementary to its efforts to develop products for the detection and treatment of atherosclerosis and vulnerable plaques in the coronary and peripheral arteries. Jomed's IVUS technology is synergistic with Volcano's Virtual Histology IVUS system, recently demonstrated at the Paris Course on Revascularization, according to Scott Huennekens, Volcano president and CEO. The California company's intravascular thermography catheter products also promise to integrate well with the pressure catheter and flow wire interventional products of Jomed's functional measurement business, he said.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.